DK0640689T3 - p4-homodimer af interleukin-12. - Google Patents

p4-homodimer af interleukin-12.

Info

Publication number
DK0640689T3
DK0640689T3 DK94109773T DK94109773T DK0640689T3 DK 0640689 T3 DK0640689 T3 DK 0640689T3 DK 94109773 T DK94109773 T DK 94109773T DK 94109773 T DK94109773 T DK 94109773T DK 0640689 T3 DK0640689 T3 DK 0640689T3
Authority
DK
Denmark
Prior art keywords
interleukin
homodimer
kda
subunits
subunit
Prior art date
Application number
DK94109773T
Other languages
English (en)
Inventor
Maurice Kent Gately
John Hakimi
Ping Ling
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0640689T3 publication Critical patent/DK0640689T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK94109773T 1993-07-02 1994-06-24 p4-homodimer af interleukin-12. DK0640689T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8783293A 1993-07-02 1993-07-02

Publications (1)

Publication Number Publication Date
DK0640689T3 true DK0640689T3 (da) 2003-02-24

Family

ID=22207513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94109773T DK0640689T3 (da) 1993-07-02 1994-06-24 p4-homodimer af interleukin-12.

Country Status (13)

Country Link
US (1) US5650492A (da)
EP (1) EP0640689B1 (da)
JP (1) JP3546076B2 (da)
AT (1) ATE226215T1 (da)
AU (1) AU675532B2 (da)
CA (1) CA2125763C (da)
DE (1) DE69431545T2 (da)
DK (1) DK0640689T3 (da)
ES (1) ES2184748T3 (da)
NZ (1) NZ260843A (da)
PT (1) PT640689E (da)
RU (1) RU2135584C1 (da)
ZA (1) ZA944567B (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
AU1407997A (en) * 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
EP0850951A4 (en) 1996-06-04 2001-04-11 Juridical Foundation NEW FELINE CYTOKINE PROTEIN
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
WO1998051327A1 (en) * 1997-05-16 1998-11-19 Toray Industries, Inc. Therapeutic agent, treatment method, prophylactic agent, and prophylactic method for canine and feline immunological diseases
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
CN101274962A (zh) * 1998-01-23 2008-10-01 霍夫曼-拉罗奇有限公司 人il-12抗体
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE19919148A1 (de) * 1999-04-27 2000-11-16 Wieser Raimund J Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP1905832A3 (en) 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) * 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
RU2003129528A (ru) * 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US8206725B2 (en) * 2003-08-26 2012-06-26 The Council Of The Queensland Institute Of Medical Research Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP
CA2526586C (en) * 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
EP1702069A2 (en) * 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
KR20090100461A (ko) 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
WO2012159100A1 (en) * 2011-05-19 2012-11-22 Rush University Medical Center Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
IL326284A (en) 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4617281A1 (en) * 2022-11-10 2025-09-17 Kanglitai Biomedical (Qingdao) Co., Ltd. Site-specific pegylated heteromeric protein or polypeptide, and preparation method therefor and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0476983B1 (en) * 1990-09-21 2000-03-15 Merck & Co. Inc. Vascular endothelial cell growth factor II
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12

Also Published As

Publication number Publication date
CA2125763A1 (en) 1995-01-03
CA2125763C (en) 2007-08-28
EP0640689A3 (en) 1995-06-28
AU675532B2 (en) 1997-02-06
ES2184748T3 (es) 2003-04-16
RU94022238A (ru) 1997-03-27
JP3546076B2 (ja) 2004-07-21
EP0640689B1 (en) 2002-10-16
EP0640689A2 (en) 1995-03-01
ZA944567B (en) 1995-12-27
AU6607294A (en) 1995-01-12
US5650492A (en) 1997-07-22
DE69431545T2 (de) 2003-06-26
ATE226215T1 (de) 2002-11-15
DE69431545D1 (de) 2002-11-21
NZ260843A (en) 1996-02-27
RU2135584C1 (ru) 1999-08-27
JPH0753594A (ja) 1995-02-28
PT640689E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
DK0640689T3 (da) p4-homodimer af interleukin-12.
DK0584125T3 (da) Afkortede former af hepatocyt vækstfaktor (HGF) receptor
EE9900492A (et) II tüüpi TGF-ß retseptori/immunoglobuliini konstantse piirkonna hübriidvalgud
NZ238403A (en) Heterocyclically-substituted phthalides and condensed analogues; herbicidal compositions thereof
ZA905150B (en) Substituted quinazolinones as angiotensin ii antagonists
ATE407950T1 (de) Löslicher interleukin-20 rezeptor
SE8901687D0 (sv) Fibronectin binding protein as well as its preparation
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
EP0886648A4 (en) COMPOSITIONS AND PEPTIDES BINDING TO THE ERYTHROPOIETIN RECEPTOR
MY123740A (en) Il-13 receptor polypeptide
ES2117623T3 (es) Receptor de la interleuquina-2 recombinante.
ATE483808T1 (de) Rezeptor für modifizierte lipoprotein niedriges molekulargewichtes
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
DK271889D0 (da) Laegemiddel paa basis af en aryloxypropanolamin til selektiv antagonisering af 5-ht1-receptorer
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
DK0648762T3 (da) Bicykliske forbindelser som excitatoriske aminosyrereceptorantagonister
MY124125A (en) Self-fusible insulated wire
DE69004821D1 (de) Polyamidharz-Zusammensetzung.
IT1271074B (it) Peptidi ad attivita' antiinfiammatoria
FI921356A0 (fi) Somatostatinreceptor.
EA200400384A1 (ru) Растворимый рецептор т-клетки
IL142464A0 (en) Non-desensitizing ampa-receptors